Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > J Liver Cancer > Volume 15(1); 2015 > Article
Review Article Role of Yttrium-90 Radioembolization in the Management of Hepatocellular Carcinoma
Do Young Kim
Journal of Liver Cancer 2015;15(1):11-18
DOI: https://doi.org/10.17998/jlc.15.1.11
Published online: March 31, 2015
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Corresponding author:  Do Young Kim,
Email: dyk1025@yuhs.ac
  • 966 Views
  • 6 Download
  • 0 Crossref
  • 0 Scopus

Yttrium-90 radioembolization has emerged as a novel therapy for hepatocellular carcinoma (HCC) of intermediate or advanced stage. Yttrium-90 has characteristics of short half-life and tissue penetration depth. Potent anti-cancer effect by this isotope enables to kill the tumor for 6 months after administration. Although transarterial chemoembolization (TACE) is the standard modality for multinodular HCC without vascular invasion, big size or numerous nodules does not allow enough treatment effect of TACE. Post-embolization syndrome resulting poor quality of life, liver dysfunction and hepatic arterial damage are other pitfalls of TACE. In several studies, radioembolization showed survival comparable to TACE, shorter hospital stay and less treatment sessions. In advanced HCC with portal vein invasion, radioembolization demonstrated similar or better survival compared with sorafenib. The atrophy of lobe treated by radioembolization and hypertrophy in the contralateral lobe can be called radiation lobectomy, which makes it possible to perform a following curative therapy. The role of radioembolization in unresectable HCC in terms of downstaging or bridge to transplantation needs to be further studied. Radioembolization is contraindicated in HCC patients with main portal vein occlusion and with poor liver function. The International guidelines for HCC have some limitations and thus rooms for radioembolization to be incorporated.


JLC : Journal of Liver Cancer